Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies
Sign Up to like & getrecommendations! Published in 2021 at "PharmacoEconomics"
DOI: 10.1007/s40273-021-01079-6
Abstract: The pipeline for new treatments for Alzheimer’s disease (AD) in the USA contains over 100 different agents, 80% of which can be categorized as disease-modifying therapies. The regulatory approval of the disease-modifying agent aducanumab has… read more here.
Keywords: alzheimer disease; contextual considerations; recommendations estimating; value ... See more keywords